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Ming-Chuan Li†, Qian-Qian Liu†, Xiao-Yun Lu*, Ya-Li Zhang and Lei-Lei WangAbstract
Background: Costimulation of T cells via costimulatory molecules such as B7 is important for eliciting cell-mediated
antitumor immunity. Presenting costimulation molecules by immobilizing recombinant B7 on the surface of
nanovectors is a novel strategy for complementary therapy. Polyhydroxyalkanoates (PHAs) are a family of
biodegradable, non-toxic, biocompatible polyesters, which can be used as a nonspecific immobilizing matrix for
protein presentation. Recombinant protein fusion with PHA granule binding protein phasin (PhaP) can be easily
immobilized on the surface of PHA nanoparticles through hydrophobic interactions between PhaP and PHA, and
therefore provides a low-cost protein presenting strategy.
Results: In this study, the extracellular domain of the B7-2 molecule (also named as CD86) was fused with PhaP at its
N-terminal and heterogeneously expressed in recombinant Escherichia coli strain BL21 (DE3). The purified B7-2-PhaP
protein was immobilized on the surface of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx)-based
nanoparticles. Loading of 240 μg (3.2 pMol) of B7-2-PhaP protein per mg nanoparticles was achieved. Immobilized
B7-2-PhaP on PHBHHx nanoparticles induced T cell activation and proliferation in vitro.
Conclusions: A PHA nanoparticle-based B7-2 costimulation molecule-presenting system was constructed. The
PHA-based B7 presenting nanosystem provided costimulation signals to induce T cell activation and expansion
in vitro. The B7-2-PhaP immobilized PHA nanosystem is a novel strategy for costimulation molecule presentation
and may be used for costimulatory molecule complementary therapy.
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It is generally accepted that the activation of naïve T cells
requires two signals. One is provided by association of
the T-cell receptor with the major histocompatibility
complex–peptide complex. The other, known as costi-
mulation, is necessary for optimal T-cell activation,
which leads to clonal T-cell expansion, cytokine secretion
and development of effector functions. Two main* Correspondence: luxy05@mail.xjtu.edu.cn
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reproduction in any medium, provided the orcostimulatory molecules, B7-1 and B7-2, accomplish the
coactivation function through binding with their ligand
CD28 on the surface of T cells [1]. Lack of costimulation
however, results in the induction of T-cell tolerance,
named anergy. This is important for tumor immunity
because a variety of tumors are potentially immunogenic
but do not stimulate an effective anti-tumor immune
response in vivo. That is partly because some tumors
can deliver antigen-specific signals to T cells, but do not
deliver costimulatory signals necessary for full activation
of T cells [2].
Low levels of B7-1 and B7-2 have been detected on
certain human cancers [3,4] and in a series of cell lines
derived from human carcinomas [2,5]. Absence ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Coomassie blue-stained SDS-PAGE of hetero-
expressed GST-B7-2-PhaP fusion protein by recombinant E. coli
BL21 (DE3) (pGEX-B72P). Lane 1: whole crude lysate of E. coli BL21
(DE3) transformed with pGEX-4T-3 plasmid. Lane 2: whole crude
lysate of E. coli BL21 (DE3) transformed with pGEX-B72P plasmid.
Protein weight marker (Institute of Biochemistry and Cell Biology,
SIBS, CAS, China) was loaded in lane M.
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“invisible” to the immune system. Accordingly, expres-
sion of B7 on tumor cells induced tumor rejection in a
murine model, suggesting that providing extra costimu-
lation molecules might render tumor cells capable of
effective antigen presentation, leading to their eradication
in vivo. Based on the safety considerations of expressing
B7 using a virus vector, we propose a novel strategy to
present costimulatory molecules by immobilizing recom-
binant B7 on the surface of polyhydroxyalkanoate
(PHAs)-based nanoparticles.
PHAs are a family of biodegradable, non-toxic, bio-
compatibility polyesters, which are synthesized by a wide
range of microorganisms [6,7], have promise as biomed-
ical materials and have been investigated for many trans-
plant applications [8]. Moreover, PHAs could also be
used as a nonspecific immobilizing matrix for protein
purification and presentation, mediated by several kinds
of PHA granule associated proteins, which contain a
hydrophobic granule-binding domain [9-13]. Among
these proteins, PHA granule binding protein phasin
(PhaP) has a high affinity for hydrophobic materials and
has been utilized to develop a low-cost protein produc-
tion system [11,12], as well as a fluorescence activated
cell sorting-based diagnostic technique [13].
In this study, the extracellular domain of the B7-2
molecule was fused with PhaP at its N-terminal and the
recombinant B7-2-PhaP protein was immobilized on the
surface of poly(3-hydroxybutyrate-co-3-hydroxyhexano-
ate) (PHBHHx)-based nanoparticles. The immunocom-
petence of the resulting fusion protein and functionality
of the PHBHHx nanoparticles were analyzed.
Results
Microbial production and purification of GST-B7-2-PhaP
fusion proteins by Escherichia coli
The PhaP gene was fused with the coding sequence for
the extracellular domain of the B7-2 molecule and was
expressed in Escherichia coli BL21 (DE3), with a gluta-
thione S-transferase (GST) tag at the N-terminal of the
resulting fusion protein. A flexible peptide linker
(GGGGSGGGSGGGS) was inserted between B7-2 and
PhaP to ensure correct folding. The GST-B7-2-PhaP
fusion protein was efficiently produced by recombinant
E. coli BL21 (DE3) (Figure 1). However, most of the
expressed intracellular fusion protein formed inclusion
bodies, probably owing to the hydrophobic nature of
PhaP. In order to increase the soluble proportion of the
fusion protein to facilitate purification, 5% (v/v) ethanol
was added to the broth during cultivation. At the same
time, the process of inducing expression was undertaken
at a low temperature of 20°C. The soluble crude proteins
obtained from lysates of E. coli were collected by sonic-
ation and centrifugation. The GST-B7-2-PhaP fusionprotein was purified by affinity chromatography using a
glutathione sepharose 4B (GS4B) column. Sodium dode-
cyl sulfate (SDS) polyacrylamide gel electrophoresis
(PAGE) analysis showed that soluble GST-B7-2-PhaP
fusion protein with a molecular mass of 73 kDa was
successfully produced in the recombinant E. coli BL21
(DE3) and a single band of the purified GST-B7-2-PhaP
fusion protein was detected from the eluted sample
(Figure 2).Preparation and characterization of nanoparticles
PHBHHx nanoparticles were prepared using the
emulsification–solvent evaporation technique described
previously [9,14]. The average diameter of prepared
nanoparticles was 198 ± 5 nm with a relative low polydis-
persity index of 0.009. Figure 3 shows the size distribu-
tion of resulting PHBHHx nanoparticles, which formed
an incipient stable colloidal suspension in aqueous
medium that could be stored for at least 1 month with-
out aggregation. The concentration of the PHBHHx
nanoparticle suspension was adjusted to 5 mg ml-1 for
further application.
Figure 2 Coomassie blue-stained SDS-PAGE of soluble GST-B7-
2-PhaP fusion protein. Lane 1: the soluble fraction was recovered
after centrifugation of whole crude lysate of E. coli BL21 (DE3)
transformed with pGEX-B72P plasmid. Lane 2: purified soluble
GST-B7-2-PhaP fusion protein. Protein weight marker (Institute of
Biochemistry and Cell Biology, SIBS, CAS, China) was loaded in
lane M.
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immobilized nanoparticles
To characterize the nanoparticles, 250 μl of 5 mg ml-1
PHBHHx nanoparticles were incubated with an equal
volume of purified GST-B7-2-PhaP fusion proteins (1-2.5
mg ml-1) for 16 h and then collected by centrifugation.
After the immobilization process and removal of the
nanoparticle proportion, no proteins were detected in
the supernatant of samples with the initiation GST-B7-2-
PhaP concentration of 1, 1.5 and 2 mg ml-1. In the sam-
ple to which 2.5 mg ml-1 GST-B7-2-PhaP protein was
added, 0.236 mg ml-1 protein remained in the super-
natant after removing the coated nanoparticles. This
indicated that approximately 400 μg of GST-B7-2-PhaP
fusion protein could be immobilized on the surface of 1
mg PHBHHx nanoparticles. Western blot analysis alsoFigure 3 Size distribution of PHBHHx nanoparticles determined
by dynamic light scattering.demonstrated that GST-B7-2-PhaP fusion proteins could
be detected on the samples eluted from the nanoparticles
(Figure 4, Lane 3, 4). A slight amount of protein could
still be detected in the supernatant when the initial pro-
tein concentration was 2.5 mg ml-1 (Figure 4, Lane 6).
However, when the protein concentration of the initial
sample was 2 mg ml-1, all GST-B7-2-PhaP fusion pro-
teins could be immobilized on the surface of PHBHHx
nanoparticles and no protein was detected in the super-
natant after incubation with PHBHHx nanoparticles
(Figure 4, Lane 5). This demonstrated that the highest
achievable amount of immobilized GST-B7-2-PhaP fu-
sion protein on the PHBHHx nanoparticles could be
as high as 400 μg per 1 mg nanoparticles.Proliferation of human T cells stimulated with B7-2-PhaP-
PHBHHx nanoparticles
Human lymphocytes were isolated from peripheral blood
donated by a healthy volunteer. The T cell population
was expanded by phytohemagglutinin stimulation. The
assembled GST-B7-2-PhaP-PHBHHx nanoparticles were
digested with thrombin to remove the GST tag. The im-
munocompetence of B7-2-PhaP-PHBHHx nanoparticles
was evaluated by T cell proliferation assay. Figure 5
shows the relative proliferation of human T cells under
different treatments.
Following in vitro phytohemagglutinin (5 μg ml-1)
stimulation, activated T cells proliferated. T cells treated
with anti-CD3 antibody (5 ng ml-1) alone received only
the primary signal for T cell activation, and thus did not
become activated or proliferate. However, addition of
either immobilized B7-2-PhaP (1 μg ml-1) or free B7-
2-PhaP protein led to significant cell expansion. The
B7-2-PhaP loaded PHBHHx nanoparticles showed a
higher activity for stimulated cell expansion than non-
immobilized free B7-2-PhaP protein. PHBHHx nano-
particle treatment also induced the stimulation of cell
proliferation. Immobilized B7-2-PhaP on PHBHHxFigure 4 Western blot analysis of GST-B7-2-PhaP fusion protein
immobilized on the surface of PHBHHx nanoparticles. Lanes 1-2:
the original GST-B7-2-PhaP protein samples with an initial
concentration of 2 and 2.5 mg ml-1, respectively. Lanes 3-4: GST-B7-
2-PhaP protein eluted from the surface of PHBHHx nanoparticles
after the immobilization procedure. Lanes 5-6: the remnant GST-B7-
2-PhaP proteins remaining in the supernatant after the
immobilization procedure. The concentration of the initial protein
sample of Lanes 3 and 5 was 2 mg ml-1, and that of Lanes 4 and 6
was 2.5 mg ml-1. Protein weight marker (Institute of Biochemistry
and Cell Biology, SIBS, CAS, China) was loaded in lane M, which was
not detected by western blot analysis.
Figure 5 Relative proliferation ratio of human peripheral blood lymphocytes by B7-2-PhaP immobilized PHBHHx nanoparticle
treatment. Lymphocytes were seeded in triplicate at 1 × 104 cells per well in 96-well culture plates, followed by incubation with the indicated
treatments for 72 h. 1: control cells; 2: cells treated with 5 μg ml-1 phytohemagglutinin; 3: cells treated with 500 ng ml-1 anti-CD3 antibody; 4:
cells treated with 5 μg ml-1 PHBHHx nanoparticles; 5: cells treated with 1 μg ml-1 B7-2-PhaP fusion protein loaded PHBHHx nanoparticles; 6: cells
treated with 1 μg ml-1 B7-2-PhaP fusion protein loaded PHBHHx nanoparticles plus 500 ng ml-1 anti-CD3 antibody; 7: cells treated with 1 μg ml-1
non-immobilized B7-2-PhaP fusion protein; 8: cells treated with 1 μg ml-1 non-immobilized B7-2-PhaP fusion protein plus 500 ng ml-1 anti-CD3
antibody. The cell proliferation was analyzed by MTT assay and the relative proliferation ratio was calculated relative to the cell proliferation level
of the control group, which was defined as 100%.
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strated the highest activity for the stimulation of cell
proliferation. These results indicated that PHBHHx-
based B7-2-PhaP presenting nanoparticles can be used
to activate T cells.
Discussion
PHAs are linear biopolyesters produced as energy- and
carbon-storage materials by many bacteria. The medical
applications of PHA have been extensively explored in re-
cent years for implant biomedical applications including
sutures, nerve conduits, patches, slings, cardiovascular
patches, stents, guided tissue repair/regeneration devices,
bone marrow scaffolds and so on. PHA nanoparticles
have also been developed as controlled drug-release vec-
tors owing to their biocompatibility and biodegradability.
The surface of PHA-based nanoparticles can be modi-
fied by many different types of signaling molecules and
thus can be used for purposes other than targeted deliv-
ery. This can also be achieved by engineering proteins
other than PhaP such as other PHA surface associated
proteins including PhaC, PhaR, and PhaZ. These proteins
provide targets for displaying various molecules on poly-
mer nanoparticle surfaces for protein immobilization and
display. The phasin PhaP is a small amphiphilic protein
that can associate with most hydrophobic polymer gran-
ule surfaces via strong hydrophobic interactions. PhaP is
abundant on the surface of natural PHA granules, andcan reach approximately 5% (wt/wt) of the total cell pro-
tein in PHA-accumulating bacteria. Thus, multifunc-
tional polymer nanoparticles can be obtained through
protein engineering of PhaP and applied to a variety of
versatile situations. The functional fusion proteins were
able to produce easily by recombinant bacteria cultiva-
tion. This method provides a simple and convenient way
to immobilize and present proteins on the surface of
hydrophobic biomaterials without complicated proce-
dures to modify both proteins and materials.
Human B7-2 is a 329-amino-acid (aa) protein contain-
ing a putative 23-aa signal peptide, a 224-aa extracellular
domain, a 21-aa transmembrane domain, and a 61-aa
cytoplasmic domain. The absence of the signal peptide,
the transmembrane domain, and the cytoplasmic do-
main did not affect the costimulatory activity of B7
molecules. In this study, the 224-aa extracellular domain
was subcloned and fused with PhaP and immobilized on
the surface of PHBHHx nanoparticles through the
hydrophobic interactions between PhaP and polymer. As
measured by western blot, 400 μg of GST-B7-2-PhaP
fusion proteins could be immobilized on the surface of
1 mg PHBHHx nanoparticles, which by extrapolation
implies 240 μg (3.2 pMol) B7-2-PhaP fusion protein
was present on the surface of 1 mg of nanoparticles.
When 1 μg ml-1 immobilized B7-2-PhaP proteins was
applied to cultured cells, the amount of nanoparticles
used was approximately 4.2 μg ml-1. Previously we
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could enhance the cell viability of rodent lymphocytes
from spleen. Interestingly, the main degradation product
of the PHBHHx polymer, 3-hydroxybutyrate, can pro-
mote interleukin-2 and interferon-γ secretion by rodent
T lymphocytes (data not published). This may explain
the slight T cell proliferation resulting from the non-
coated PHBHHx nanoparticle treatment in this study.
Phytohemagglutinin is a lectin found in plants, and
is used as a mitogen to trigger T lymphocyte cell div-
ision. Isolated lymphocytes were treated with 5 μg ml-1
phytohemagglutinin to increase cell numbers prior to
the proliferation assay. Thus, the expanded cells were
mainly T cells, although small numbers of B cells and
other monocytes remained in the culture. This may
explain why non-immobilized B7-2-PhaP fusion proteins
also resulted in cell proliferation. PhaP is a bacterial
protein that might be recognized by B cells, thus trig-
gering an immune response resulting in lymphocyte
proliferation. However, whether the B7-2-PhaP fusion
protein was immobilized or not, the combined treat-
ment of B7-2-PhaP protein and anti-CD3 antibody
achieved the highest proliferation ratio and number of
activated T cells. Compared with the non-immobilized
free B7-2-PhaP protein, the B7-2-PhaP protein loaded
nanoparticles showed a higher activity for cell prolifera-
tion stimulation. This can be explained by the advantage
of the immobilization system, which can be used to pro-
vide several signal molecules that interact concurrently
with ligands on cell surfaces.
Conclusions
In this study, a novel PHA nanoparticle-based B7 costi-
mulation molecule-presenting system was developed.
Both the vehicle and the presented functional protein
were produced by microorganism fermentation and
purified from the culture broth. The extracellular do-
main of the B7-2 molecule was fused with PhaP, and the
B7-2-PhaP protein was hetero-expressed by recombinant
E. coli BL21 (DE3). The purified B7-2-PhaP protein was
immobilized on the surface of PHBHHx nanoparticles
through the hydrophobic interaction between PhaP and
polymer. The immunocompetence study showed that
the PHA-based B7 presenting nanosystem could provide
costimulatory signals for T cell activation, leading to
T cell expansion in vitro. The B7-2-PhaP immobilized
PHA nanosystem provides a novel strategy for the pres-
entation of costimulatory molecules and may be a useful
tool for costimulation molecule complementary therapy.
Methods
Plasmid construction
The DNA sequence coding for the extracellular domain
of human B7-2 molecule (52-672bp) was subcloned fromthe plasmid B7-2(IgV+C)/TEasy, which contains the
cDNA sequence of B7-2. The gene encoding PhaP of
Ralstonia eutropha H16 was subcloned from the plasmid
pTwin2-EPhaP (donated by the Laboratory of Microbiol-
ogy, Department of Biological Science and Biotechno-
logy, Tsinghua University, Beijing, China). The primers B1
(5’-GCGGATCCATGGCTCCTCTGAAGATTC-3’) (the
double line marks the BamHI restriction site) and B2
(5’-ACCAGAGCCACCTCCTGAACCGCCTCCACCTG-
TAATCCAAGGAATG-3’) were used to amplify extracel-
lular domain of B7-2 coding sequence. The primers
P1 (5’-GGTTCAGGAGGTGGCTCTGGTGGATCGCTC
ACCCCGGAACAAGTT-3’) and P2 (5’-CGCTCGAGA
GCCGTCGTCTTCTTTGCCGT-3’) (the double line
marks the XhoI restriction site) were used to amplify the
PhaP gene. The PCR products of B7-2 and PhaP were
mixed at the ratio of 1:1 and fusion with each other by
overlap extension PCR. Then BamHI and XhoI digested
B7-2-phaP segment was inserted into the corresponding
sites downstream of the GST tag coding sequence of
pGEX-4T-3 expression vector to generate the final plas-
mid pGEX-B72P (Figure 6).
Cultivation of strains and expression of recombinant
protein
E. coli strain BL21 (DE3) was used to express GST-B7-2-
PhaP fusion proteins. E. coli BL21 (DE3) transformants
carrying the pGEX-B72P plasmid was cultured at 37°C
in 500 ml shake flasks containing 200 ml Luria Bertani
medium (1% w/v Bacto tryptone, 0.5% yeast extract, and
1% NaCl) supplemented with 100 mg ml-1 ampicillin
and 3% (v/v) ethanol in a shaking incubator at 200 rpm.
At an OD600 of 0.4-0.6, 0.1 mM isopropyl β-D-
thiogalactopyranoside was added to induce the expres-
sion of the fusion gene and the recombinant E. coli
BL21 (DE3) carrying pGEX-B72P was continued in cul-
ture at 20°C for another 6 hours.
Recombinant protein purification and characterization
Cells were harvested by centrifugation at 6000 × g for
10 min and re-suspended in 20 ml phosphate-buffered
saline (PBS) buffer followed by sonication (Ultrasonic
crasher, Scientz-II D, Ningbo, China) for 10 min at
40% output. After centrifugation at 12000 × g for 30 min
at 4°C, the clarified soluble protein fraction was collected.
The target recombinant GST-B7-2-PhaP fusion protein
was purified by GS4B affinity chromatography (GE
Healthcare, USA) according to the manufacturer’s
protocol.
The eluted protein was purified and condensed by the
dialysis bag method. Sample collected after purification
was analyzed by 12% SDS-PAGE. The purified recom-
binant protein was stored at −20°C after lyophilization
for further usage.
Figure 6 Plasmid map of pGEX-B72-P. pGEX-B72-P was derived from plasmid pGEX-4T-3 which contains the pBR322 origin. B7-2: coding
sequence for 224-aa extracellular domain of human B7-2 costimulatory molecule; phaP: coding sequence of PHA associated protein phasin
(PhaP); Amp: ampicillin resistance gene; Lac I: coding sequence of Lac operon DNA-binding transcriptional repressor.
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The PHBHHx material was produced, isolated and
characterized as described previously [15,16]. The
PHBHHx nanoparticles were fabricated by a modified
emulsification/solvent diffusion method [17,18]. Briefly,
20 mg of PHBHHx polymer was added into 1 ml chloro-
form. Five milliliters of 1% poly(vinyl alcohol) (PVA) (w/v)
was sonicated for 1 min and was slowly added to 1 ml of
organic solution. The double emulsion was then sonicated
using a probe sonicator (Sonics & Materials, Newtown,
CT, USA) for 5 min and the mixed solution was moder-
ately stirred with a magnetic mixer for 6 h to solidify the
nanodroplets. Chloroform was removed by volatilization
at room temperature. The nanoparticles were collected by
centrifugation at 38000 rpm for 60 min, followed by wash-
ing twice with deionized water. The particle size was ana-
lyzed by a laser light scattering machine (Zetasizer Nano
ZS, Malvern, UK).
Immobilization and characterization of fusion proteins on
nanoparticles
Fusion protein GST-B7-2-PhaP was dissolved in PBS at
a final concentration of 1-2.5 mg ml-1. A concentration
of 5 mg ml-1 of PHBHHx nanoparticles was mixed with
various amounts of purified GST-B7-2-PhaP fusion
proteins, followed by stirring and incubation at 4°C for
12-16 h. Subsequently, the colloidal system was collected
by centrifugation at 12,000 × g for 30 min and washedtwice with PBS. The immobilized GST-B7-2-PhaP fusion
protein was calculated according to the difference be-
tween the amounts of protein in the initial sample and
that in the supernatant after incubation, and was quanti-
fied using the bicinchoninic acid method using a protein
assay kit Beyotime (#P0010, Beyotime Institute of Bio-
technology, China) according to the manufacturer’s
protocol.
The assembled GST-B7-2-PhaP-PHBHHx nanoparti-
cles were resuspended in protein loading buffer (50 mM
Tris-HCl (pH 6.8), 2% SDS, 0.1% bromophenol blue,
10% glycerol, 1% β-mercaptoethanol) and boiled for
2 min to allow detachment of denatured GST-B7-2-PhaP
fusion protein from PHBHHx nanoparticles. After
12,000 × g centrifugation for 10 min, the supernatant was
analyzed by SDS-PAGE and western blot to verify the
immobilization of GST-B7-2-PhaP on the surface of
PHBHHx nanoparticles. Briefly, proteins were trans-
ferred to poly (vinylidene fluoride) (PVDF) membranes
after electrophoresis, and were then blocked for 1 h at
room temperature with 5% bovine serum albumin in
TBST buffer. PVDF membranes were incubated over-
night with an anti-GST antibody (CW0084, Beijing
CWBio Co., Ltd., China). The PVDF membrane was
subsequently hybridized with secondary horseradish
peroxidase-conjugated goat anti-mouse IgG (CW0084,
Beijing CWBio Co., Ltd., China) and the recombinant pro-
tein was detected by incubating with a chemiluminescence
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Thermo Scientific Inc., Bremen, Germany) according to
the manufacturer’s instructions.
Lymphocyte separation, cell culture and proliferation
assay
Five milliliters of whole blood was donated by a healthy
volunteer. Lymphocytes were separated from non-
coagulated whole blood using a human lymphocyte
separation medium according to the manufacturer’s
instructions (PAN Biotech, Aidenbach, Germany). The
isolated cells were suspended in a culture bottle with
high-glucose RPMI1640 medium (Gibco, UK) supple-
mented with 10% fetal bovine serum (Gibco, UK) and
maintained at 37°C in a humidified 5% CO2 atmosphere
overnight. After disposal of adherent cells, the suspended
cells were recovered and treated with 5 μg ml-1 phyto-
hemagglutinin for 72 h to expand the T cell population.
For the T cell proliferation assay, cells were passaged and
seeded in triplicate at 1 × 104 cells per well in 96-well cul-
ture plates, followed by incubation with the correspond-
ing treatment for another 72 h. The cell proliferation was
analyzed by MTT assay. Cells treated with 5 μg ml-1
phytohemagglutinin served as the positive control. T-cell
surface glycoprotein CD3 antibody (500 ng ml-1) was
used to provide the first signal for T cell activation.
Statistical analysis
All results were expressed as mean± standard deviation
of experiments performed in triplicate. Statistical differ-
ences were evaluated using a one-way analysis of variance
with a Student’s t-test. Differences were considered to be
statistically significant when P< 0.05.
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